Baird reiterates an Outperform rating on BioMarin Pharmaceutical (Nasdaq: BMRN), raises price target to $28.

Baird analyst says, "Remain buyers ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE